Researchers at Moffitt Cancer Center have identified distinct spatial tumor–immune ecosystems that predict whether patients with advanced non–small cell lung cancer will benefit from immunotherapy.

The US Food and Drug Administration (FDA) has fast-tracked a promising new gene therapy, KB707, which is inhaled as a fine mist for the targeted treatment of advanced or metastatic non-small-cell lung ...